NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics today announced a collaboration to validate the Centre of Excellence for the Prevention of Organ Failure's (PROOF Centre) assay for organ rejection in heart transplant patients.

HTG will use the HTG Edge System in the clinical laboratory of St. Paul's Hospital, Providence Health Care in Vancouver, British Columbia to start clinical validation of the PROOF Centre's molecular biomarker test, which is intended to help physicians better monitor and treat patients after a heart transplant.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

The House of Lords in the UK approves a bill to allow mitochondrial donation.